What Is EHR Phenotyping and Why Does It Matter for NHS Research?
By Dr Mohsin Masood, PhD | TechAlpha Ltd | May 2026
If you work in NHS analytics, health data research, or the pharmaceutical industry, you’ve likely encountered the term EHR phenotyping. But what does it actually mean, and why is it one of the most important tools available to health data scientists working with UK patient data today?
In this article, we explain EHR phenotyping in plain terms, explore why it matters for NHS research and Real-World Evidence (RWE) generation, and outline how organisations can use it effectively.
What Is an Electronic Health Record (EHR)?
An Electronic Health Record (EHR) is a digital record of a patient’s health history. In the UK, EHR data is collected across multiple settings:
- Primary care: GP consultations, diagnoses, prescriptions (e.g. CPRD, The Phoenix Partnership)
- Secondary care: Hospital admissions, procedures, diagnoses (e.g. Hospital Episode Statistics / HES)
- Mortality data: Death registrations and cause of death (ONS)
- Disease registries: Condition-specific datasets
The NHS holds one of the richest EHR datasets in the world, covering a population of over 65 million patients, from birth to death, across primary and secondary care. This makes UK EHR data uniquely valuable for health research, Real-World Evidence and pharmacovigilance.
What Is EHR Phenotyping?
EHR phenotyping is the process of identifying patients with a specific disease, condition, or clinical characteristic using data recorded in their electronic health records.
In simple terms, it is how researchers define “who has condition X” using the data available in EHR systems.
For example, if a pharmaceutical company wants to study patients with Type 2 Diabetes using NHS data, they cannot simply ask the database for a list. Instead, they need a phenotyping algorithm: a set of rules that searches the EHR for the right combination of:
- Diagnosis codes (e.g. Read codes, ICD-10, SNOMED CT)
- Prescriptions (e.g. metformin, insulin)
- Lab test results (e.g. HbA1c levels)
- Clinical measurements
- Referrals and procedures
The result is a validated, reproducible definition of the patient population — a phenotype.
Why Is EHR Phenotyping So Important?
1. It Is the Foundation of Real-World Evidence
Real-World Evidence (RWE) studies use data from clinical practice, rather than controlled trials, to understand how treatments work in real patients. Before any RWE study can begin, researchers must define their study population accurately. EHR phenotyping is how that definition is created.
A poorly defined phenotype leads to:
- Misclassified patients (including patients who don’t have the condition)
- Biased study results
- Regulatory rejection of evidence submissions
A well-validated phenotype leads to:
- Accurate patient cohorts
- Robust and reproducible findings
- Evidence that stands up to regulatory scrutiny (MHRA, FDA, EMA)
2. It Enables NHS Data to Be Used for Research
NHS organisations, universities and pharmaceutical companies regularly apply to access large-scale NHS datasets — such as those held by NHS England, CPRD, or through Trusted Research Environments (TREs) like OpenSAFELY or the NHS Research Sandbox.
To use these datasets, researchers must define their study population using validated phenotyping algorithms. Without this, data access applications are unlikely to be approved.
3. It Supports Drug Safety and Pharmacovigilance
Pharmaceutical companies have a regulatory obligation to monitor the safety of their medicines in real-world use, known as pharmacovigilance. EHR phenotyping is essential for identifying:
- Patients who have been prescribed a specific drug
- Adverse events or side effects in EHR data
- Contraindicated conditions that may affect drug safety signals
4. It Is Critical for Rare Disease Research
For rare conditions such as Pulmonary Hypertension, Hereditary Haemorrhagic Telangiectasia, or rare cancers, the patient population in any single hospital is too small for meaningful research. EHR phenotyping across national datasets allows researchers to identify every patient with a rare condition across England, creating cohorts large enough to generate meaningful evidence.
5. It Supports NHS Service Planning and Analytics
NHS commissioners and Integrated Care Boards (ICBs) use EHR phenotyping to:
- Identify undiagnosed patient populations
- Understand disease prevalence across regions
- Plan workforce and resource allocation
- Measure health inequalities
Key Challenges in EHR Phenotyping
EHR phenotyping sounds straightforward, but in practice, it is complex. Common challenges include:
Coding Inconsistency
NHS EHR data uses multiple clinical coding systems, Read codes (primary care), ICD-10 (secondary care diagnoses), OPCS (procedures), SNOMED CT (increasingly used), and dm+d (medicines). Phenotyping requires expertise across all of these systems.
Data Quality
EHR data is recorded for clinical purposes, not research. This means:
- Some conditions are undercoded or miscoded
- Free-text data is not always captured in structured fields
- Recording practices vary between GP practices and hospitals
Validation
A phenotype must be validated to confirm it accurately identifies the intended patient population. Validation approaches include:
- Comparing against the gold-standard clinical records
- Calculating positive predictive value (PPV)
- Cross-referencing against disease registries
Portability Across Datasets
A phenotype developed for CPRD may not perform equally well in HES or SUS data. Phenotype portability across datasets requires careful design and testing.
The OMOP Common Data Model: A Game Changer
One of the most significant developments in EHR phenotyping is the OMOP Common Data Model (CDM), an international standard for structuring health data developed by the OHDSI (Observational Health Data Sciences and Informatics) network.
By converting NHS data into OMOP CDM format, organisations can:
- Run phenotyping algorithms across multiple datasets simultaneously
- Share and reuse phenotypes internationally
- Conduct federated analyses without data leaving the organisation
- Comply with international research standards
TechAlpha Ltd has expertise in OMOP CDM implementation and can support NHS organisations and pharmaceutical companies in converting existing datasets to OMOP format.
How TechAlpha Ltd Can Help
At TechAlpha Ltd, EHR phenotyping is one of our core specialisms. Dr Mohsin Masood (PhD) has extensive experience developing, validating and implementing EHR phenotyping algorithms across UK datasets, including CPRD, HES, SUS and bespoke NHS trust data.
Our EHR phenotyping services include:
Phenotype development: designing algorithms using Read codes, ICD-10, SNOMED CT, OPCS and dm+d
Phenotype validation: rigorous validation using multiple evidence approaches, including PPV calculation and registry cross-referencing
OMOP CDM implementation: converting existing datasets to OMOP format for international research standards
Rare disease phenotyping: specialist expertise in rare conditions, including Pulmonary Hypertension
Data access support: helping organisations design phenotyping strategies for NHS data access applications (NHS England, CPRD, OpenSAFELY)
Training and knowledge transfer: building in-house phenotyping capability within NHS and research organisations
Summary
EHR phenotyping is not a niche technical skill — it is the foundation of modern health data research. Whether you are generating Real-World Evidence for a regulatory submission, conducting NHS service analytics, or researching rare diseases, the quality of your phenotyping determines the quality of your results.
As NHS datasets grow richer and more accessible through Trusted Research Environments and OMOP standardisation, the demand for expert EHR phenotyping will only increase.
Get in Touch
If your organisation needs support with EHR phenotyping — whether for a Real-World Evidence study, an NHS data access application, or a pharmacovigilance project: TechAlpha Ltd is here to help.
📧 dr.masood@techalphaltd.co.uk 🌐 techalphaltd.co.uk/get-started
Dr Mohsin Masood is the founder of TechAlpha Ltd and a specialist in EHR phenotyping, Real-World Evidence, OMOP CDM and health data science. He has worked with NHS organisations, universities, pharmaceutical companies and CROs across the UK and internationally.
Tags: EHR Phenotyping, NHS Analytics, Real-World Evidence, OMOP CDM, Health Data Science, Pharmacovigilance, NHS Research, UK Health Data, CPRD, HES
